Chemical inhibitors of C2orf30 target various aspects of cell cycle regulation, a process in which this protein is involved. Palbociclib, a selective inhibitor of cyclin-dependent kinases CDK4 and CDK6, disrupts the cell cycle progression, leading to the inhibition of C2orf30 function. This is because C2orf30's activity is closely tied to the cell cycle, and by halting the cycle, Palbociclib effectively hinders the protein's role. Similarly, Roscovitine targets a broad spectrum of CDKs, which are essential for controlling the progression of the cell cycle. By inhibiting these kinases, Roscovitine can suppress the function of C2orf30. Alsterpaullone also acts as a potent inhibitor of CDKs, and in doing so, can inhibit the function of C2orf30 by impeding the cell cycle processes that this protein facilitates.
Continuing along the same mechanism, Indirubin, Olomoucine, and Flavopiridol serve as inhibitors of CDKs. The inhibition of these kinases by Indirubin and Olomoucine can inhibit the function of C2orf30 by preventing the cell cycle events that C2orf30 is associated with. Flavopiridol, with its ability to inhibit several CDKs, disrupts cell cycle regulation and in turn, the function of C2orf30. Ribociclib and PD0332991 (Palbociclib) specifically inhibit CDK4/6 and by interfering with these particular kinases, they can inhibit the function of C2orf30 through the disruption of cell cycle events. AT7519, a multi-CDK inhibitor, can inhibit the function of C2orf30 by interfering with the general progression of the cell cycle. Milciclib, which affects various CDKs, can prevent the cell cycle-related functions of C2orf30, thus inhibiting the protein's function. Furthermore, Dinaciclib, a potent inhibitor of several CDKs, affects cell cycle control, leading to the inhibition of C2orf30. Lastly, SNS-032, by selectively inhibiting CDKs 2, 7, and 9, disrupts processes central to C2orf30's role in cell cycle regulation, achieving the inhibition of the protein's function. Each of these chemicals exerts its inhibitory effect by targeting the cell cycle, subsequently hindering the functional role of C2orf30 within this vital cellular process.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Palbociclib | 571190-30-2 | sc-507366 | 50 mg | $321.00 | ||
Palbociclib is a selective inhibitor of cyclin-dependent kinases CDK4 and CDK6. C2orf30 is involved in cell cycle regulation; inhibition of CDKs can disrupt the cell cycle progression, thereby inhibiting the function of C2orf30. | ||||||
Roscovitine | 186692-46-6 | sc-24002 sc-24002A | 1 mg 5 mg | $94.00 $265.00 | 42 | |
Roscovitine targets cyclin-dependent kinases (CDKs) which are crucial for cell cycle control. As C2orf30 is implicated in cell cycle regulation, inhibition of these kinases can lead to the functional inhibition of C2orf30. | ||||||
Alsterpaullone | 237430-03-4 | sc-202453 sc-202453A | 1 mg 5 mg | $68.00 $312.00 | 2 | |
Alsterpaullone is a potent inhibitor of CDKs. By inhibiting these key cell cycle regulators, the function of C2orf30, which is involved in cell cycle regulation, can be inhibited. | ||||||
Indirubin | 479-41-4 | sc-201531 sc-201531A | 5 mg 25 mg | $114.00 $525.00 | 4 | |
Indirubin is known to inhibit CDKs, and since C2orf30 has a role in cell cycle regulation, such inhibition can impede the cell cycle processes that C2orf30 is involved in, thereby inhibiting its function. | ||||||
Olomoucine | 101622-51-9 | sc-3509 sc-3509A | 5 mg 25 mg | $72.00 $274.00 | 12 | |
Olomoucine is a CDK inhibitor that can arrest cell cycle progression. This could inhibit the function of C2orf30, which is associated with cell cycle regulation, by preventing necessary cell cycle events. | ||||||
Flavopiridol | 146426-40-6 | sc-202157 sc-202157A | 5 mg 25 mg | $78.00 $259.00 | 41 | |
Flavopiridol inhibits several CDKs involved in cell cycle regulation. As C2orf30's function is related to cell cycle control, disruption of CDK activity can result in the inhibition of C2orf30's function. | ||||||
PD 0332991 Isethionate | 827022-33-3 | sc-478943 | 1 mg | $300.00 | ||
PD0332991, also known as Palbociclib, is a CDK4/6 inhibitor, which can lead to cell cycle arrest and thereby inhibit C2orf30, which is involved in cell cycle regulation. | ||||||
AT-7519 Hydrochloride | 902135-91-5 | sc-482715 | 5 mg | $125.00 | ||
AT7519 is a multi-CDK inhibitor that can interfere with cell cycle progression. By doing so, it may inhibit C2orf30's function in cell cycle regulation. | ||||||
Trametinib | 871700-17-3 | sc-364639 sc-364639A sc-364639B | 5 mg 10 mg 1 g | $114.00 $166.00 $947.00 | 19 | |
Milciclib is a CDK inhibitor affecting various CDKs involved in cell cycle progression. Inhibiting these kinases can prevent the cell cycle-related functions of C2orf30, thus inhibiting the protein's function. | ||||||
Dinaciclib | 779353-01-4 | sc-364483 sc-364483A | 5 mg 25 mg | $247.00 $888.00 | 1 | |
Dinaciclib is a strong inhibitor of several CDKs, and by inhibiting these kinases, it can affect the cell cycle control in which C2orf30 is implicated, leading to its functional inhibition. | ||||||